organization · Reporting owner
AJU IB Investment Co., Ltd.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apellis Pharmaceuticals, Inc.
Report date November 13, 2017 · Filed November 13, 2017
Section 16 reporting ended · disclosed 2017-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,292,062 |
Reported balance
After 2017-11-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-11-13 · Conversion · Acquired 2,292,062 · Balance 2,292,062 F1: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-13 · Conversion · Disposed 4,000,000 · Balance 0 F1: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-13 · Conversion · Disposed 888,969 · Balance 0 F1: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund.
Rein Therapeutics, Inc.
Report date July 05, 2017 · Filed July 07, 2017
Section 16 reporting ended · disclosed 2017-07-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 443,973 |
Reported balance
After 2017-07-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-07-05 · Conversion · Acquired 443,973 · Balance 443,973 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person"). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 492,629 |
Reported balance
After 2017-07-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-07-05 · Conversion · Acquired 48,656 · Balance 492,629 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 517,558 |
Reported balance
After 2017-07-05 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-07-05 · Purchase · Acquired 24,929 · Balance 517,558 F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person"). |
| Series E-3 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-07-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-05 · Conversion · Disposed 4,411,765 · Balance 0 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person"). |
| Series F Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2017-07-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-07-05 · Conversion · Disposed 483,501 · Balance 0 F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person").
F3: The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2017 Filed Nov 13, 2017 21:29 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries D Preferred Stock · Derivative | 888,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026036 · doc4.xml · derivative · entry 3 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 416,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 21:29 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionSeries C Preferred Stock · Derivative | 4,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-026036 · doc4.xml · derivative · entry 2 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,875,293 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 21:29 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | ConversionCommon Stock | 2,292,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-026036 · doc4.xml · nonDerivative · entry 1 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,292,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series C and Series D Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C and Series D Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund ("AJU Platform Fund"), which is managed by AJU IB Investment Co., Ltd. Ji-won Kim, Kwang-sun Yang and Yong-jin Choi, the directors of AJU Platform Fund, share voting and dispositive control over the shares held by such fund. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 23:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries F Preferred Stock · Derivative | 483,501 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018090 · doc4.xml · derivative · entry 5 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 48,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 23:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries E-3 Preferred Stock · Derivative | 4,411,765 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018090 · doc4.xml · derivative · entry 4 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 443,973 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person"). Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 23:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 24,929 | $15.00 | $373,935.00 |
DisclosureSEC source: 0000899243-17-018090 · doc4.xml · nonDerivative · entry 3 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 517,558 F2 · ownership.nature: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person"). Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 23:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionCommon Stock | 48,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-018090 · doc4.xml · nonDerivative · entry 2 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 492,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: The shares reported herein are held of record by AJU Growth & Healthcare Fund, which is managed by the Reporting Person. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 23:13 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionCommon Stock | 443,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-018090 · doc4.xml · nonDerivative · entry 1 AJU IB Investment Co., Ltd. · CIK 0001710065 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 443,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.nature: The shares reported herein are held of record by AJU Life Science Overseas Expansion Platform Fund, which is managed by AJU IB Investment (the "Reporting Person"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.